Effective management of pediatric AML relapse risk requires precise prognostic tools. A significant report from the Children's Oncology Group (COG) recently evaluated the role of HLA-DR expression at diagnosis. Specifically, researchers wanted to see if this marker could predict which children might experience a recurrence after an allogeneic hematopoietic stem cell transplant (HSCT). However, the study results demonstrate that HLA-DR expression does not offer clear predictive value for post-transplant relapse.

Improving the Assessment of Pediatric AML Relapse Risk

The investigators reviewed data from numerous pediatric cases to find patterns in post-transplant outcomes. Consequently, they discovered that initial HLA-DR status did not correlate with the likelihood of the disease returning. Therefore, doctors should not rely on this marker when tailoring transplant protocols. Instead, medical teams must prioritize established factors like cytogenetic risk and minimal residual disease (MRD) levels. These elements remain the gold standard for identifying high-risk patients. Furthermore, this study suggests that the biological drivers of relapse post-HSCT differ from those present at initial diagnosis. Thus, continuous monitoring of MRD remains far more critical than diagnostic immunophenotype alone.

Additionally, identifying new biomarkers remains essential for improving survival rates. While HLA-DR identifies myeloid cells, it does not seem to influence the graft-versus-leukemia effect. Because of this, scientists are now exploring other genetic and epigenetic changes that might bypass the immune system. Ultimately, this research helps clinicians refine their focus toward markers that truly impact patient survival.

Frequently Asked Questions

Does HLA-DR expression affect the success of a stem cell transplant in pediatric AML?

No. According to the latest COG report, HLA-DR expression levels at diagnosis do not significantly impact the risk of relapse or overall success following an allogeneic transplant.

What markers are better for predicting pediatric AML relapse risk?

Clinicians find that cytogenetic abnormalities and the presence of minimal residual disease (MRD) are much more accurate predictors of relapse risk than initial HLA-DR expression.

Why is HLA-DR used during the initial diagnosis of leukemia?

HLA-DR is a common surface marker used in flow cytometry to identify and classify myeloid blasts. While it helps confirm an AML diagnosis, it does not appear to serve as a long-term prognostic indicator for transplant outcomes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Chinnabhandar V et al. HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2026 Mar 26. doi: 10.3324/haematol.2025.288751. PMID: 41885017.


2. Huang BJ, et al. Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. J Clin Oncol. 2025;43(17):1961-1971.